Bookbuilding IPO | ₹1,952 Cr | Listed at BSE, NSE | Wed, Jul 3, 2024 - Fri, Jul 5, 2024
Emcure Pharmaceuticals IPO is a book build issue of ₹1,952.03 crores. The issue is a combination of fresh issue of 0.79 crore shares aggregating to ₹800.58 crores and offer for sale of 1.14 crore shares aggregating to ₹1,151.45 crores.
Emcure Pharmaceuticals IPO bidding started from Jul 3, 2024 and ended on Jul 5, 2024. The allotment for Emcure Pharmaceuticals IPO was finalized on Jul 8, 2024. The shares got listed on BSE, NSE on Jul 10, 2024.
Emcure Pharmaceuticals IPO price band is set at ₹1,008 per share. The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,112 (14 shares) (based on upper price). The lot size investment for sNII is 15 lots (210 shares), amounting to ₹2,11,680, and for bNII, it is 71 lots (994 shares), amounting to ₹10,01,952.
The issue includes a reservation of up to 1,08,900 shares for employees offered at a discount of ₹90.00 to the issue price.
Kotak Mahindra Capital Co.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Emcure Pharmaceuticals IPO RHP for detailed Information.
IPO Open
Wed, Jul 3, 2024
IPO Close
Fri, Jul 5, 2024
Issue Price
₹1008 per share
Market Cap (Pre-IPO)
₹19,029.89 Cr
| IPO Date | 3 to 5 Jul, 2024 |
| Listed on | Wed, Jul 10, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹960 to ₹1008 |
| Issue Price | ₹1008 per share |
| Lot Size | 14 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹90.00 |
| Total Issue Size | 1,93,75,070 shares (agg. up to ₹1,952 Cr) |
| Fresh Issue | 79,46,231 shares (agg. up to ₹801 Cr) |
| Offer for Sale | 1,14,28,839 shares of ₹10 (agg. up to ₹1,151 Cr) |
| Share Holding Pre Issue | 18,08,52,116 shares |
| Share Holding Post Issue | 18,87,88,623 shares |
| BSE Script Code / NSE Symbol | 544210 / EMCURE |
| ISIN | INE168P01015 |
Emcure Pharmaceuticals IPO offers total 1,93,75,070 shares. Out of which 96,33,084 (49.72%) allocated to QIB, 38,53,234 (19.89%) allocated to QIB (Ex- Anchor), 28,89,926 (14.92%) allocated to NII 67,43,160 (34.80%) allocated to RII and 57,79,850 (29.83%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 96,33,084 (49.72%) | NA |
| − Anchor Investor Shares Offered | 57,79,850 (29.83%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 38,53,234 (19.89%) | NA |
| NII (HNI) Shares Offered | 28,89,926 (14.92%) | NA |
| − bNII > ₹10L | 19,26,618 (9.94%) | 9,174 |
| − sNII < ₹10L | 9,63,308 (4.97%) | 4,587 |
| Retail Shares Offered | 67,43,160 (34.80%) | 4,81,654 |
| Employee Shares Offered | 1,08,900 (0.56%) | NA |
| Total Shares Offered | 1,93,75,070 (100.00%) |
Investors can bid for a minimum of 14 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,112 |
| Retail (Max) | 14 | 196 | ₹1,97,568 |
| S-HNI (Min) | 15 | 210 | ₹2,11,680 |
| S-HNI (Max) | 70 | 980 | ₹9,87,840 |
| B-HNI (Min) | 71 | 994 | ₹10,01,952 |
Emcure Pharmaceuticals IPO raises ₹582.61 crore from anchor investors. Emcure Pharmaceuticals IPO Anchor bid date is July 2, 2024.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, Jul 2, 2024 |
| Shares Offered | 57,79,850 |
| Anchor Portion (₹ Cr.) | 582.61 |
| Anchor lock-in period end date for 50% shares (30 Days) | Wed, Aug 7, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sun, Oct 6, 2024 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.
In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company's total revenue, respectively. The company's Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.
Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.
As of September 30, 2023, the company's marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Total Income | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| NET Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Reserves and Surplus | 2,722.40 | 2,293.77 | 1,791.03 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company | 800.00 |
| 2 | General corporate purposes | 41.14 |
| KPI | |
|---|---|
| ROE | 16.90% |
| ROCE | 19.37% |
| Debt/Equity | 0.67 |
| RoNW | 16.87% |
| PAT Margin | 7.86% |
| Price to Book Value | 6.18 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 29.17 | 27.95 |
| P/E (x) | 34.55 | 36.07 |
| Promoter Holding | 83.21% | 78.08% |
| Market Cap | ₹19,029.89 Cr. |
The Emcure Pharma IPO is subscribed 67.87 times on July 5, 2024 6:20:06 PM (Day 3). The public issue subscribed 7.36 times in the retail category, 191.24 times in the QIB category, and 49.32 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 191.24 | 38,53,234 | 73,68,91,932 |
| NII | 49.32 | 28,89,926 | 14,25,25,866 |
| bNII (bids above ₹10L) | 54.9 | 19,26,618 | 10,57,70,490 |
| sNII (bids below ₹10L) | 38.16 | 9,63,309 | 3,67,55,376 |
| Retail | 7.36 | 67,43,160 | 4,96,18,884 |
| Employee | 8.81 | 1,08,900 | 9,59,756 |
| Total | 67.87 | 1,37,03,538 | 92,99,96,438 |
Total Application : 28,45,226
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 51.15 |
| 2 | Commission/ processing fees for SCBs, Sponsor Banks, Bankers to the Offer, brokerage, selling commission, bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs | 7.20 |
| 3 | Fee payable to the Registrar to the Offer | 0.80 |
| 4 | Listing fees, SEBI filing fees, BSE & NSE processing fees, book building software fees, NSDL and CDSL fee and other regulatory expenses, | 10.20 |
| 5 | Printing and stationery expenses | 1.57 |
| 6 | Fees payable to the Statutory Auditor, Independent Chartered Accountant, industry service provider, IPR consultant, independent chartered engineer and ROC consultant | 7.90 |
| 7 | Advertising and marketing expenses for the Offer | 8.41 |
| 8 | Fees payable to the legal counsel | 8.11 |
| 9 | Miscellaneous | 4.95 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,008.00 | ₹1,008.00 |
| Open | ₹1,325.05 | ₹1,325.05 |
| Low | ₹1,325.05 | ₹1,325.05 |
| High | ₹1,384.00 | ₹1,385.00 |
| Last Trade | ₹1,358.85 | ₹1,359.15 |
Emcure Pharmaceuticals IPO is a main-board IPO of 1,93,75,070 equity shares of the face value of ₹10 aggregating up to ₹1,952 Crores. The issue is priced at ₹1008 per share. The minimum order quantity is 14.
The IPO opens on Wed, Jul 3, 2024, and closes on Fri, Jul 5, 2024.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Emcure Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Emcure Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Emcure Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Emcure Pharmaceuticals IPO opens on Wed, Jul 3, 2024 and closes on Fri, Jul 5, 2024.
Emcure Pharmaceuticals IPO lot size is 14, and the minimum amount required for application is ₹14,112.
You can apply in Emcure Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Emcure Pharmaceuticals IPO will be done on Monday, July 8, 2024, and the allotted shares will be credited to your demat account by Tue, Jul 9, 2024. Check the Emcure Pharmaceuticals IPO allotment status.
The Emcure Pharmaceuticals IPO listing date is on Wed, Jul 10, 2024.
